GSK plc 6-K, filed Jul 18, 2022
GSK plc (GSK)
6-K
2022-07-18
For: 2022-07-18
View Original
Added on
July 04, 2026
About this 6-K
GSK plc filed this 6-K on July 18, 2022.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
Form 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR
15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the
month of July 2022
Commission
File Number 001-15170
GSK plc
(Translation
of registrant's name into English)
980 Great West Road, Brentford, Middlesex, TW8 9GS
(Address
of principal executive office)
Indicate
by check mark whether the registrant files or will file annual
reports under cover of Form 20-F or Form 40-F.
Form
20-F . . . .X. . . . Form 40-F . . . . . . . .
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(1): ____
Indicate
by check mark if the registrant is submitting the Form 6-K in paper
as permitted by Regulation S-T Rule 101(b)(7): ____
Issued: 18 July 2022, London UK
Completion of the demerger of Haleon and share consolidation of
GSK
GSK plc (LSE/NYSE: GSK) has today (Monday 18 July 2022) completed
the demerger of the Consumer Healthcare business from the GSK Group
to form the Haleon Group. The shares of Haleon plc (ticker "LSE:
HLN") will be admitted at 8.00 a.m. today to the Premium Listing
segment of the Official List and to trading on the Main Market of
the London Stock Exchange ("LSE").
It is expected that American Depositary Shares representing shares
of Haleon plc (ticker: "NYSE: HLN") ("Haleon ADSs") will commence
"regular-way" trading on the New York Stock Exchange (the "NYSE")
at market open on Friday 22 July 2022. In addition, we expect that
Haleon ADSs will begin trading on a "when-issued" basis on the NYSE
from market open today up to and including Thursday 21 July 2022.
Each Haleon ADS represents two Haleon ordinary shares.
GSK Share Consolidation
At the GSK General Meeting on 6 July 2022, alongside the demerger,
GSK shareholders also approved the consolidation of GSK shares (the
"GSK Share Consolidation"). The GSK Share Consolidation is expected
to take place after the market closes today. It is expected that
admission and dealings in the new GSK shares on the LSE will
commence at 8.00 a.m. on Tuesday 19 July 2022. GSK will provide an
update following the completion of the GSK Share Consolidation at
around 7.00 a.m. on Tuesday 19 July 2022.
The ratio for the GSK Share Consolidation cannot be fixed at this
time as it will depend on fluctuations in the volume and price of
the GSK shares in the period between 8.00 a.m. and 4.30 p.m.
today.
As at the time of this announcement, GSK's issued share capital
consists of 5,389,096,045 ordinary shares of 25 pence each
(including 304,905,950 ordinary shares held in treasury).
Therefore, the total number of voting rights in the Company is
5,084,190,095. If the total number of GSK shares in issue prior to
the record time at 8.00 p.m. today is not exactly divisible by the
denominator in the consolidation ratio, then shortly before the GSK
Share Consolidation, GSK will issue up to 49 ordinary shares to
ensure that following the GSK Share Consolidation there are no
fractional ordinary shares outstanding.
Further information on and key dates in relation to the proposed
demerger of Haleon and the GSK Share Consolidation is set out at
the end of this announcement ("Expected Timetable of Principal
Events") and can also be found in the Circular to Shareholders
published on 1 June 2022. The Circular is available on GSK's
website at www.gsk.com/demerger.
Victoria Whyte
Company Secretary
18 July 2022
Disclaimer
GSK
makes no representation or warranty as to the appropriateness,
accuracy, completeness or reliability of the information in this
announcement.
This
announcement is for information purposes only and is not intended
to and does not constitute or form part of any offer or invitation
to purchase, otherwise acquire, subscribe for, sell, otherwise
dispose of or issue, or any solicitation of any offer to sell,
otherwise dispose of, issue, purchase, otherwise acquire or
subscribe for, any security.
Expected Timetable of Principal Events
The
times and dates set out in the timetable below and throughout this
announcement are indicative only and based on GSK's current
expectations and may be subject to change without further
notice.
|
Event
|
Time and date(1)
|
|
Commencement
of dealings in Existing GSK Shares (ex entitlement to Haleon
Shares) on the LSE
|
8
a.m. on Monday 18 July 2022
|
|
Admission
and commencement of dealings in Haleon Shares on the
LSE
|
8
a.m. on Monday 18 July 2022
|
|
CREST
accounts credited in respect of Haleon Shares in uncertificated
form
|
As
soon as practicable after 8 a.m. on Monday 18 July
2022
|
|
GSK
Share Consolidation record time--
|
8
p.m. on Monday 18 July 2022
|
|
GSK
Share Consolidation becomes effective
|
After
8 p.m. on Monday 18 July 2022
|
|
GSK
Admission and commencement of dealings in New GSK Shares on the
LSE
|
8
a.m. on Tuesday 19 July 2022
|
|
CREST
accounts credited in respect of New GSK Shares in uncertificated
form
|
As
soon as practicable after 8 a.m. on Tuesday 19 July
2022
|
|
Commencement
of trading in Haleon ADSs on a "when-issued" basis on the
NYSE
|
9.30
a.m. New York City time on Monday 18 July 2022
|
|
Commencement
of "regular-way" trading in Haleon ADSs on the NYSE
|
9.30
a.m. New York City time on Friday 22 July 2022
|
|
Admission and commencement of dealings
in new
GSK ADSs on the NYSE
|
9.30
a.m. New York City time on Friday 22 July 2022
|
|
Opening of the GSK ADS issuance and cancellation
books (2)
|
8
a.m. New York City time on Monday 25 July 2022
|
|
Latest date for despatch of:
- definitive share certificates (where applicable)
for New GSK Shares in certificated form to Qualifying Shareholders
on the GSK Share Register
|
By
Monday 1 August 2022
|
|
- CSN statements for GSK CSN(3)
|
By
Monday 1 August 2022
|
|
- definitive share certificates (where applicable)
for Haleon Shares in certificated form to Qualifying Shareholders
on the GSK Share Register(4)
|
By
Thursday 4 August 2022
|
|
- opening statements for Haleon
CSN(3)
(4)
|
By
Thursday 4 August 2022
|
|
Posting
of payment advice, CREST accounts credited or payment by electronic
payment in respect of fractional entitlements arising from the GSK
Share Consolidation
|
Week
commencing Monday 1 August 2022
|
Notes
(1)
Unless otherwise indicated, all references to time in this
timetable are to UK time.
(2) The
Depositary will suspend the issuance and cancellation of GSK ADSs
from Thursday 14 July 2022 until Monday 25 July 2022. This means
that during this time, you will not be able to convert your GSK
ADSs into GSK Shares, surrender your GSK ADSs and receive
underlying GSK Shares, or deposit your GSK Shares and receive GSK
ADSs. However, the closing of the issuance and cancellation books
does not impact trading, and you may continue to trade your GSK
ADSs during this period.
(3) For
CSN Shareholders who have a Shareview Portfolio account, and have
not elected for paper statements to be issued to them, the CSN
statements will only be made available electronically via their
account.
(4) Subject
to the timing of the Haleon Capital Reduction.
About GSK
GSK is a global biopharma company with a purpose to unite science,
technology, and talent to get ahead of disease together. Find out
more at www.gsk.com/about-us
|
GSK enquiries
|
|
|
|
|
Media:
|
Tim Foley
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Madeleine Breckon
|
+44 (0) 20 8047 5502
|
(London)
|
|
|
Kathleen Quinn
|
+1 202 603 5003
|
(Washington DC)
|
|
|
|
|
|
|
Investor Relations:
|
Nick Stone
|
+44 (0) 7717 618834
|
(London)
|
|
|
James Dodwell
|
+44 (0) 20 8047 2406
|
(London)
|
|
|
Mick Readey
|
+44 (0) 7990 339653
|
(London)
|
|
|
Josh Williams
|
+44 (0) 7385 415719
|
(London)
|
|
|
Jeff McLaughlin
|
+1 215 751 7002
|
(Philadelphia)
|
Cautionary statement regarding forward-looking
statements
GSK
cautions investors that any forward-looking statements or
projections made by GSK, including those made in this announcement,
are subject to risks and uncertainties that may cause actual
results to differ materially from those projected. Such factors
include, but are not limited to, those described in the Company's
Annual Report on Form 20-F for 2021, GSK's Q1 Results for 2022 and
any impacts of the COVID-19 pandemic.
Registered in England & Wales:
No.
3888792
Registered Office:
980
Great West Road
Brentford,
Middlesex
TW8
9GS
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf
by the undersigned, thereunto duly authorised.
|
|
GSK plc
|
|
|
(Registrant)
|
|
|
|
|
Date: July
18, 2022
|
|
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
|
|
Victoria Whyte
|
|
|
Authorised
Signatory for and on
|
|
|
behalf
of GSK plc
|